EA202192625A1 - Лиганды псевдокиназы tyk2 - Google Patents

Лиганды псевдокиназы tyk2

Info

Publication number
EA202192625A1
EA202192625A1 EA202192625A EA202192625A EA202192625A1 EA 202192625 A1 EA202192625 A1 EA 202192625A1 EA 202192625 A EA202192625 A EA 202192625A EA 202192625 A EA202192625 A EA 202192625A EA 202192625 A1 EA202192625 A1 EA 202192625A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ligands
tyk2
pseudokinase
describes
tyk2 pseudokinase
Prior art date
Application number
EA202192625A
Other languages
English (en)
Russian (ru)
Inventor
Раджу Мохан
Джон Насс
Джэйсон ХАРРИС
Шэньдун ЮАНЬ
Original Assignee
Вентикс Байосайенсес, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вентикс Байосайенсес, Инк. filed Critical Вентикс Байосайенсес, Инк.
Publication of EA202192625A1 publication Critical patent/EA202192625A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EA202192625A 2019-03-26 2020-03-25 Лиганды псевдокиназы tyk2 EA202192625A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962824144P 2019-03-26 2019-03-26
PCT/US2020/024746 WO2020198379A1 (en) 2019-03-26 2020-03-25 Tyk2 pseudokinase ligands

Publications (1)

Publication Number Publication Date
EA202192625A1 true EA202192625A1 (ru) 2022-03-21

Family

ID=72612101

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192625A EA202192625A1 (ru) 2019-03-26 2020-03-25 Лиганды псевдокиназы tyk2

Country Status (13)

Country Link
US (2) US11780842B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946350A4 (cg-RX-API-DMAC7.html)
JP (1) JP7595582B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220004641A (cg-RX-API-DMAC7.html)
CN (1) CN113874021B (cg-RX-API-DMAC7.html)
AU (1) AU2020247990A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019070A2 (cg-RX-API-DMAC7.html)
CA (1) CA3134814A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192625A1 (cg-RX-API-DMAC7.html)
IL (1) IL286635A (cg-RX-API-DMAC7.html)
MX (1) MX2021011723A (cg-RX-API-DMAC7.html)
SG (1) SG11202110523XA (cg-RX-API-DMAC7.html)
WO (1) WO2020198379A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66346B1 (sr) 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
US20220177486A1 (en) * 2019-03-11 2022-06-09 Esker Therapeutics, Inc. Tyk2 inhibitors and uses thereof
SG11202110523XA (en) 2019-03-26 2021-10-28 Ventyx Biosciences Inc Tyk2 pseudokinase ligands
CN114929226B (zh) * 2019-11-08 2024-09-27 温缇克斯生物科学公司 Tyk2假激酶配体
IL301385A (en) * 2020-09-16 2023-05-01 Alumis Inc TYK2 inhibitors and their use
WO2022117090A1 (zh) * 2020-12-03 2022-06-09 成都科岭源医药技术有限公司 一种多环化合物及其制备方法和用途
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
WO2023208244A1 (zh) * 2022-04-29 2023-11-02 南京明德新药研发有限公司 大环类化合物及其应用
CN118084923A (zh) * 2022-11-17 2024-05-28 中国科学院上海有机化学研究所 作为lrrk2激酶抑制剂的环状化合物及其制备方法
EP4692096A4 (en) * 2023-03-31 2026-07-22 Prime Gene Therapeutics Co Ltd MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND ITS USE

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP4564485B2 (ja) 2003-02-28 2010-10-20 帝人ファーマ株式会社 ピラゾロ[1,5−a]ピリミジン誘導体
US20070082900A1 (en) 2005-10-06 2007-04-12 Schering Corporation Methods for inhibiting protein kinases
US7517882B2 (en) 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
WO2010118207A1 (en) 2009-04-09 2010-10-14 Schering Corporation Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
WO2015112806A2 (en) 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
RU2732405C2 (ru) 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
RS63359B1 (sr) 2015-11-06 2022-07-29 Incyte Corp Heterociklična jedinjenja kao inhibitori pi3k-gama
AU2017302019A1 (en) 2016-07-28 2019-02-07 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
KR102477063B1 (ko) * 2016-10-28 2022-12-12 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물
AU2018230737B2 (en) 2017-03-08 2022-09-22 Takeda Pharmaceutical Company Limited Tyk2 inhibitors, uses, and methods for production thereof
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2018213365A1 (en) 2017-05-15 2018-11-22 Dana-Farber Cancer Institute, Inc. Compounds for treating dengue virus infection and other viral infections
IL317854A (en) * 2017-07-28 2025-02-01 Takeda Pharmaceuticals Co TYK2 inhibitors and their uses
EP3849981B1 (en) 2018-09-10 2023-02-01 Eli Lilly and Company Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
JP7619951B2 (ja) 2018-10-15 2025-01-22 武田薬品工業株式会社 Tyk2阻害剤およびその使用
TWI800696B (zh) 2018-12-10 2023-05-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
SG11202108619SA (en) 2019-02-07 2021-09-29 Ventyx Biosciences Inc Tyk2 pseudokinase ligands
US20220177486A1 (en) 2019-03-11 2022-06-09 Esker Therapeutics, Inc. Tyk2 inhibitors and uses thereof
SG11202110523XA (en) 2019-03-26 2021-10-28 Ventyx Biosciences Inc Tyk2 pseudokinase ligands
CN114929226B (zh) 2019-11-08 2024-09-27 温缇克斯生物科学公司 Tyk2假激酶配体

Also Published As

Publication number Publication date
IL286635A (en) 2021-10-31
WO2020198379A1 (en) 2020-10-01
MX2021011723A (es) 2021-10-22
CA3134814A1 (en) 2020-10-01
EP3946350A1 (en) 2022-02-09
SG11202110523XA (en) 2021-10-28
EP3946350A4 (en) 2022-09-07
CN113874021A (zh) 2021-12-31
JP7595582B2 (ja) 2024-12-06
US20230406858A1 (en) 2023-12-21
JP2022529311A (ja) 2022-06-21
US11780842B2 (en) 2023-10-10
KR20220004641A (ko) 2022-01-11
CN113874021B (zh) 2024-07-09
US20220169651A1 (en) 2022-06-02
AU2020247990A1 (en) 2021-11-11
BR112021019070A2 (pt) 2022-02-15

Similar Documents

Publication Publication Date Title
PH12022551105A1 (en) Tyk2 pseudokinase ligands
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
EA202091708A1 (ru) Ингибиторы днк-пк
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
EA201990187A1 (ru) Антипролиферационные средства на основе пиримидина
EA201791874A1 (ru) Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201990400A1 (ru) Соединения и композиции и их применение
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
MX2024005705A (es) Composiciones de liquidos ionicos.
MA53765B2 (fr) Tubulysines et conjugués tubulysines-protéines
MX2022000712A (es) Moduladores de nlrp3.
EA202091559A1 (ru) Способ получения модуляторов соматостатина
MX2021013602A (es) Inhibidores de jak.
EA201991898A1 (ru) Двойные ингибиторы magl и faah
EA202090414A1 (ru) Соединения и их применение
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
BR112021014566A2 (pt) Moduladores de gpr35
BR112022005608A2 (pt) Inibidores de jak
EA202191115A1 (ru) Новые пиридазины
EA202190766A1 (ru) Иммуномодуляторы, их композиции и способы применения